Skip to content

Condition

Prostate Cancer

Prostate cancer is the most common non-skin cancer in American men. Modern imaging and targeted biopsy have transformed how it is diagnosed, staged, and treated, often without traditional surgery or radiation.

Multiparametric prostate MRI used to localize suspected prostate cancer before targeted biopsy

Overview

  • An MRI-targeted, image-guided diagnostic pathway reduces unnecessary biopsies and finds clinically significant cancers earlier.
  • Many low- and intermediate-risk cancers are now candidates for focal therapy or active surveillance instead of whole-gland treatment.
  • Treatment plans balance cancer control with preservation of urinary and sexual function.

Symptoms

  • Most early prostate cancers cause no symptoms, detection relies on PSA and imaging.
  • Rising PSA over time, or a new abnormal digital rectal exam.
  • Less commonly: difficulty urinating, blood in urine or semen, or new bone pain.

How it is diagnosed

  • PSA blood test and clinical exam.
  • Multiparametric prostate MRI to identify suspicious zones (PI-RADS scoring).
  • MRI-fusion targeted biopsy of suspicious areas plus systematic sampling.
  • Genomic testing of biopsy tissue when intermediate-risk to guide treatment intensity.

Treatment options

FAQ

Questions about prostate cancer

Answers patients most commonly ask before their consultation.

No. PSA can rise from BPH, prostatitis, recent ejaculation, or instrumentation. A persistent or rising PSA usually warrants prostate MRI before biopsy.

Ready to talk?

Personalized urologic care begins with a conversation.

Schedule a consultation to review your imaging, lab work, and treatment options.